Biohaven Ltd.

Investment bank RBC Capital Markets <a href="https://www.cnbc.com/2026/01/21/this-biotech-stock-has-plummeted-over-the-past-year-rbc-says-it-sees-a-big-gain-ahead.html">upgraded</a>&nbsp;to "outperform"&nbsp;its rating on shares of Biohaven Ltd, a small cap developer of drugs for epilepsy and kidney disease. The upgrade follows new clinical data that, in RBC’s view, reduces development risk and improves the risk-reward profile. The bank now sees potential for the stock to rise 70% from current levels.

RBC Capital upgrades TP and rating on small-cap biotech Biohaven, seeing 70% upside

MAIA Biotechnology, Inc.

Shares of <a href="https://finance.yahoo.com/quote/MAIA/">MAIA Biotechnology</a>, a micro-cap developer of a cancer drug designed to “<a href="https://oninvest.com/article/obmanut-rakovuu-kletku-pocemu-akciam-maia-prognoziruut-semikratnyj-rost">trick</a>” tumor cells, surged 26% on Monday, January 20, to their highest level since May 2025. The company’s lead therapy is moving closer to potential regulatory approval in the U.S., which MAIA <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/166/maia-biotechnology-advances-ateganosine-cancer-treatment">described</a>&nbsp;as a “clear value-creation inflection point” for shareholders.

Biotech MAIA soars 26% as potential FDA approval means 'inflection point'

GSK plc

RAPT Therapeutics, Inc.

Shares of RAPT Therapeutics, a developer of long-acting therapies for food allergies, <a href="https://finance.yahoo.com/quote/RAPT/">surged</a>&nbsp;nearly 64% in premarket trading on Tuesday, January 20, after the company <a href="https://investors.rapt.com/news-releases/news-release-details/gsk-enters-agreement-acquire-rapt-therapeutics">announced</a>&nbsp;its acquisition at a premium by pharma giant GSK.

Allergy pill developer RAPT soars on announcement of acquisition by GSK 

Eli Lilly and Company

ABIVAX Societe Anonyme

Eli Lilly could reportedly pay twice the market price for Abivax; six months ago, Abivax shares jumped sixfold in a day on news of successful trials of its lead drug

French biotech Abivax jumps 20% on news of possible takeover by Eli Lilly

Tesla, Inc.

Amazon.com, Inc.

Planet Labs PBC

Tennant Company

Serve Robotics Inc.

Richtech Robotics Inc.

Novo Nordisk A/S

Alphabet Inc.

Taiwan Semiconductor Manufacturing Company Limited

Leader Harmonious Drive Systems Co., Ltd.

There is one problem with new technologies - they are, in fact, new. Only those who can prove their maturity reach the stock exchange. Based on the results of the turbulent year 2025, I tried to find out which public companies may become beneficiaries of scientific and technological progress in 2026.

What technologies will drive markets in 2026: space, AI, robots and biotechs

Ventyx Biosciences, Inc.

Shares of Ventyx Biosciences, a small-cap developer of anti-inflammatory drugs, jumped nearly 70% in early trading on Wednesday, January 7, after the <i>Wall Street Journal</i> <a href="https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2">reported</a>&nbsp;that Eli Lilly is in talks to acquire the biotech.

Small biotech Ventyx soars 70% amid 'advanced talks' with Eli Lilly to be acquired

Cardiff Oncology, Inc.

Shares in Cardiff Oncology could rise more than fourfold from current levels, according to <a href="https://dashboard.channelchek.com/wp-content/uploads/pdf/CRDF_20260105_27958.pdf">Noble Capital Markets</a>, which has initiated coverage of the biotech. Cardiff is developing a therapy targeting a form of colorectal cancer for which many standard treatments are ineffective.

Noble initiates on Cardiff Oncology with fourfold expected upside

Capricor Therapeutics, Inc.

Shares of biotech Capricor Therapeutics have <a href="https://www.marketwatch.com/investing/stock/capr?mod=search_symbol">surged</a>&nbsp;about 530% over the past month after the company reported positive results from a <a href="https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results">phase III trial</a>&nbsp;of its experimental therapy, deramiocel, for a rare disease called Duchenne muscular dystrophy. If the drug receives regulatory approval, Capricor shares could rise another 75%, according to Wall Street.

Biotech Capricor soars 530% in last month; Wall Street still sees more upside

The YTD gain for the French biotech is still almost 1,300% 

STOXX 600 YTD leader Abivax tumbles 10% in a day on 9m25 earnings

Ligand Pharmaceuticals Incorporated

Amgen Inc.

Merck & Co., Inc.

Pfizer Inc.

Gilead Sciences, Inc.

Equity investors should take a closer look at mid-cap Ligand Pharmaceuticals for a more conservative bet on the biotech industry, Citigroup argues. In his initiation report (as quoted by <a href="https://www.cnbc.com/2025/12/09/a-biotech-stock-for-investors-scared-to-invest-in-the-risky-industry.html">CNBC</a>), Citi analyst Yigal Nochomovitz highlights Ligand as "the 'Goldilocks’ pick for investors seeking exposure to biotech upside while mitigating volatility” thanks to its broad portfolio of products.

Citi spotlights Ligand as 'Goldilocks’ pick' for conservative biotech investors

Structure Therapeutics Inc.

Shares of Structure Therapeutics more than doubled on Monday, December 8, closing near $70 apiece, with <a href="https://finance.yahoo.com/quote/GPCR/">the company’s market capitalization</a> rocketing above $4.2 billion. This followed mid-stage trial results for its experimental oral obesity drug, aleniglipron, which <a href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">delivered</a>&nbsp;greater weight loss than a <a href="https://lilly.mediaroom.com/2025-08-07-Lillys-oral-GLP-1,-orforglipron,-delivers-weight-loss-of-up-to-an-average-of-27-3-lbs-in-first-of-two-pivotal-Phase-3-trials-in-adults-with-obesity">competing pill</a> under development by Eli Lilly. Analysts say the stock may have further upside, particularly if a major player moves to acquire the company.

Structure shares double after 'near-homerun' obesity pill data

VolitionRx Limited

Shares of VolitionRx, a micro cap developer of blood-drop tests for cancer and sepsis, <a href="https://finance.yahoo.com/quote/VNRX/">jumped</a>&nbsp;9.5% yesterday, December 4. The company <a href="https://ir.volition.com/news-events/press-releases/detail/860/volitionrx-limited-announces-the-first-sale-of-the-nu-q-cancer-assays-for-clinical-certification-in-preparation-for-routine-clinical-use">reported</a>&nbsp;that France has selected its sepsis test for early disease detection in hospitals. Overall, Wall Street <a href="https://www.marketwatch.com/investing/stock/vnrx/analystestimates?mod=mw_quote_tab">believes</a>&nbsp;VolitionRx shares still have 730% upside.